Ken Griffin Tyra Biosciences, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Tyra Biosciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 21,600 shares of TYRA stock, worth $300,240. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,600Holding current value
$300,240% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding TYRA
# of Institutions
98Shares Held
43.5MCall Options Held
353KPut Options Held
1.1K-
Ra Capital Management, L.P. Boston, MA10.4MShares$145 Million3.41% of portfolio
-
Boxer Capital, LLC San Diego, CA6.45MShares$89.6 Million8.05% of portfolio
-
Bvf Inc San Francisco, CA4.66MShares$64.8 Million3.48% of portfolio
-
Canaan Partners Xi LLC Menlo Park, CA4.41MShares$61.3 Million97.89% of portfolio
-
Nextech Invest Ag4.06MShares$56.4 Million15.55% of portfolio
About Tyra Biosciences, Inc.
- Ticker TYRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,973,600
- Market Cap $583M
- Description
- Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The comp...